Three months later, on Nov
In response, leading pharmas have announced massive capacity expansions: Novo Nordisk plans a $4.1 billion manufacturing facility in North Carolina ( [5] ) (opening ~2029), and Lilly has committed over $15 billion for new plants in Indiana, Wisconsin, Pennsylvania, and Alabama ( [6] ) ( [7] ) ( [8] ) ( [9] )
This modification stabilizes the molecule against dipeptidyl peptidase IV degradation while preserving full GHRH receptor activity
Long-term safety data continues to accumulate, and a comprehensive 2024 review in Diabetes Care by Daniel Drucker concluded that the overall risk-benefit profile of GLP-1 medicines remains favorable for their approved indications
If I were going to invest in a supplement, I would want a form designed for better delivery, not just higher dosage
Weich, N